ClinicalTrials.gg

Program

relmapirazin

Also written as “MB-102”, “Lumitrace” and “MB-102 and commercially available optical angiography imaging system”.

Its studies are mostly in Renal Insufficiency · Retinal Diseases · Blastic Plasmacytoid Dendritic Cell Neoplasm · Renal Insufficiency, Chronic · Acute Kidney Injury, led by 3 companies.

Furthest: phase 3, since Apr 21, 20228 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediBeacon62 open or runningphase 3since Apr 21, 2022May 10, 2016Dec 2026phase 1 · NCT07080008
Huadong Medicine10 open or runningphase 3since Mar 22, 2023Mar 22, 2023none ahead
Mustang Bio10 open or runningphase 2since Sep 25, 2019Sep 25, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2016First study: phase 2 study in Acute Kidney InjuryNew to MediBeaconMediBeacon · NCT02772276 · 234 enrolled · United States
  2. May 22, 20192 early phase 1 studiesMediBeacon · NCT04008121, NCT03962998
  3. Sep 25, 2019Mustang Bio's first study: phase 2 study in Blastic Plasmacytoid Dendritic Cell NeoplasmNew to Mustang BioMustang Bio · NCT04109482 · 3 enrolled · United States
  4. Apr 21, 2022Phase 3 study in Renal Insufficiency, ChronicMediBeacon · NCT05425719 · 249 enrolled · United States, China
  5. Mar 8, 2023Phase 3 study in Kidney DiseasesMediBeacon · NCT05777174 · 149 enrolled · United States
  6. Mar 22, 2023Huadong Medicine's first study: phase 3 study in Kidney DiseasesNew to Huadong MedicineHuadong Medicine · NCT05943977 · 121 enrolled · China
  7. Jul 15, 2025Phase 1 study in Ureter InjuryMediBeacon · NCT07080008 · 10 enrolled · United States

Ahead

  1. Dec 2026Primary completion: phase 1 study in Ureter InjuryMediBeacon · NCT07080008
  2. Dec 2026Primary completion: early phase 1 study in Retinal DiseasesMediBeacon · NCT04008121

TargetBeta

IL3RA →read by rule
“A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA) and ”NCIt, by rule

Other programs on IL3RA

ProgramCompanyFurthest phaseStudies
pivekimab sunirineruleAbbViephase 34

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07080008Ureter Injury · United States1Active, not recruitingMediBeaconDec 202610
NCT05943977Kidney Diseases · China3CompletedHuadong MedicineNov 30, 2023121
NCT05777174Kidney Diseases · United States3CompletedMediBeaconApr 15, 2024149
NCT05425719Renal Insufficiency, Chronic · United States, China3CompletedMediBeaconFeb 15, 2023249
NCT04109482Blastic Plasmacytoid Dendritic Cell Neoplasm · United States2TerminatedMustang BioMay 17, 20233
NCT04008121Retinal Diseases · United StatesEarly 1RecruitingMediBeaconDec 202610
NCT03962998Crohn Disease · United StatesEarly 1CompletedMediBeaconOct 5, 202122
NCT02772276Acute Kidney Injury · United States2CompletedMediBeaconAug 4, 2021234

How it is read

Names in the registry

  • “MB-102”, 4 entries
  • “Lumitrace”, 1 entry
  • “MB-102 and commercially available optical angiography imaging system”, 1 entry
  • “MB-102 OMID”, 1 entry
  • “MB-102-- single dose of 4 µmol/kg”, 1 entry

Codes read as this program: MB102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.